Strengthening migraine literacy at the New Zealand Nurse Practitioner Conference 2026
The New Zealand Nurse Practitioner Conference 2026 was a valuable opportunity for Migraine Foundation Aotearoa New Zealand to connect with nurse practitioners and share the most-up-date information, resources and best practice guidelines. An estimated 400 nurse practitioners attended the biannual conference, held at QT Rydge’s Queenstown, 17–19 June 2026. About 140 nurse practitioners made a […]
Growing understanding of migraine highlighted at Rotorua GPCME 2026
Migraine Foundation was back for our second year exhibiting at the Rotorua General Practice Conference & Medical Exhibition (GPCME) this month, with an education stand at the 3-day conference. The 2026 Rotorua GPCME was attended by over 1,000 healthcare professionals working within primary care, held at the Rotorua Energy Events Centre from 11–14 June 2026. […]
Rizatriptan supply issue
We have been made aware of a supply issue that is affecting rizatriptan 10mg tablets (Rizamelt), which is the most commonly used triptan in Aotearoa for the treatment of migraine attacks. Apparently this is due to manufacturing issues and re-supply is expected in November. People who are using Rizamelt can access an alternative brand of […]
Updated article on migraine for primary care health professionals
One of the most trusted sources of up-to-date and evidence based information about health conditions and treatment options is the Best Practice Advisory Centre New Zealand (bpacNZ). This is a New Zealand not-for-profit organisation that develops and disseminates ‘best practice’ information to GPs and others through their website, reports, email communications and social media. GPs […]
Pharmac consultation on possible brand changes
Each year, Pharmac gives pharmaceutical suppliers the opportunity to bid for being the ‘main supplier’ (up to 95%) for a range of medicines. This is called the ‘annual tender’ and means that a medicine currently supplied by one company may switch to a different branded product (e.g. the non-steroidal anti-inflammatory drug ibuprofen in the past […]
Health professional resources endorsed by the Royal New Zealand College of GPs
We’re delighted to announce that our Preventive medications for migraine and Treatment of acute migraine attacks factsheets we developed for health professionals have been endorsed by the Royal New Zealand College of General Practitioners (RNZCGP). This means the RNZCGP has recognised these as being evidence-based, relevant, of a high quality and appropriate for general practice […]
Migraine discussions at Pasifika Festival 2026
For the first time, migraine was included in the list of health topics being discussed at the Hub at Pasifika Festival on 14-15 March 2026 – alongside heart health, stroke, kidney health, breast cancer and bowel cancer. Migraine may not cause premature death, like some cancers, but it can bring a level of misery that […]
Migraine Foundation will be at Pasifika Festival 2026
The Migraine Foundation team is delighted to be a stallholder at the 2026 Pasifika Festival in March. This is the first time we’re attending the event, which is on 14–15 March at Western Springs, Auckland. Thanks to a generous grant from Aoteoroa Gaming Trust, we’ll have our patient trifold brochure available in six languages – […]
Lasmiditan – the migraine drug we didn’t even get to try
The best medications we currently have to treat migraine attacks are the triptans. In Aotearoa New Zealand, we have two of these: sumatriptan and rizatriptan. But although these can be very effective if taken early in an attack, they don’t work for everyone. And some people can’t take them because they constrict blood vessels, which […]
Fremanezumab (Ajovy) now available in New Zealand
The start of 2026 marks further progress for access to calcitonin gene-related peptide (CGRP) medications for Kiwis, with the launch of fremanezumab (Ajovy) in New Zealand this month. Ajovy is the fourth anti-CGRP medication now available in New Zealand. Like the other two injectable CGRP monoclonal antibody medications (Emgality and Aimovig), Ajovy is administered by […]
